News Conference News AHA 2025 Metformin Before Catheter Ablation for AF Helps Nondiabetic Patients With Overweight Caitlin E. Cox November 18, 2025
News Conference News AHA 2025 POLY-HF: Polypill Pays Dividends in Patients With HFrEF Todd Neale November 14, 2025
News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD Todd Neale November 13, 2025
News Conference News AHA 2025 Beta-blockers Not Helpful After MI in Patients With Preserved EF Yael L. Maxwell November 12, 2025
News Conference News AHA 2025 Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids Michael O'Riordan November 10, 2025
News Conference News AHA 2025 Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI Todd Neale November 09, 2025
News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News AHA 2025 One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients Todd Neale November 08, 2025
News Conference News AHA 2025 Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia Caitlin E. Cox November 08, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Conference News AHA 2024 REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients L.A. McKeown November 22, 2024
News Conference News AHA 2024 Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN Caitlin E. Cox November 22, 2024
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
Presentation AHA 2024 Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks Presenter: Steven E. Nissen November 18, 2024
Presentation AHA 2024 Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial Presenter: Marcely Gimenes Bonatto November 18, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2024 OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain Todd Neale November 18, 2024